血清hsa-miR-486-5p在乳腺癌早期诊断中的价值

目的 探讨与乳腺癌早期诊断密切相关的血清microRNA(miRNA)的临床价值。方法 对乳腺癌发生发展4个阶段（正常-非典型增生-原位癌-浸润性癌）的组织进行miRNA高通量测序，以得到与疾病进展密切相关的目标miRNA，进而利用RT-qPCR技术分析目标miRNA在4个阶段血清中的表达情况。结果 hsa-miR-486-5P在乳腺癌发生发展4个阶段的组织和血清中均随疾病进展呈下调状态，在早期乳腺癌患者血清中呈明显低表达，与乳腺癌分子分型无关（P>0.05）。早期乳腺癌组低表达的血清hsa-miR-486-5p与正常对照组相比呈显著差异性（P<0.01）；ROC曲线分析结果显示ROC曲线下面积（AUC值）为81.2%（95%CI： 0.707～0.917），灵敏度和特异度分别为62.5%和90.3%。结论 血清hsa-miR-486-5p可以作为诊断早期乳腺癌的生物标志物，具有较高的临床应用价值。

Clinical value of serum hsa-miR-486-5p in detecting early-stage breast cancer

Objective To assess the clinical value of serum microRNAs (miRNAs) in early diagnosis of breast cancer. Methods High-throughput sequencing was performed to obtain target miRNAs in tissue samples of normal breast tissue, atypical hyperplasia, carcinoma in situ and invasive breast cancer. RT-qPCR was used to detect the expression level of the target miRNAs in serum samples from 24 healthy female subjects, 10 cases breast atypical hyperplasia, 22 cases carcinoma in situ and 40 cases of invasive breast cancer. Results The expression of hsa-miR-486-5P in tissue and serum decreased with the development and progression of breast cancer. It was significantly decline in the serum of early-stage breast cancer patients but had no relationship with breast cancer molecular subtypes(P>0.05). The serum expression of hsa-miR-486-5p in early-stage breast cancer patients was significantly lower than that in normal controls (P<0.01). The ROC curve analysis showed that the area under the curve was 81.2% (95%CI: 0.707-0.917), the sensitivity and specificity were 62.5% and 90.3%, respectively. Conclusion Serum hsa-miR-486-5p might be used as a biomarker for the diagnosis of early-stage breast cancer.